Gentian Diagnostics AS (GENT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gentian Diagnostics AS (GENT) has a cash flow conversion efficiency ratio of 0.208x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr42.59 Million ≈ $4.48 Million USD) by net assets (Nkr204.96 Million ≈ $21.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Gentian Diagnostics AS balance sheet quality to measure how much of total assets are equity-financed.
Gentian Diagnostics AS - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Gentian Diagnostics AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Gentian Diagnostics AS cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Gentian Diagnostics AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gentian Diagnostics AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Haemato AG
HM:HAEK
|
N/A |
|
Skarbiec Holding S.A.
WAR:SKH
|
-1.431x |
|
All Cosmos Bio-Tech Holding Corp
TW:4148
|
0.078x |
|
Kamux Suomi Oy
HE:KAMUX
|
0.181x |
|
kenturn Nano Tec Co Ltd
TWO:4561
|
-0.005x |
|
NEW ZEALAND RURAL
F:8UK
|
N/A |
|
Tu Liem Urban Development JSC
VN:NTL
|
-0.024x |
|
Mercor S.A.
WAR:MCR
|
-0.262x |
Annual Cash Flow Conversion Efficiency for Gentian Diagnostics AS (2013–2025)
The table below shows the annual cash flow conversion efficiency of Gentian Diagnostics AS from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see GENT market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr204.96 Million ≈ $21.57 Million |
Nkr42.59 Million ≈ $4.48 Million |
0.208x | +199.65% |
| 2024-12-31 | Nkr194.05 Million ≈ $20.42 Million |
Nkr13.46 Million ≈ $1.42 Million |
0.069x | -34.22% |
| 2023-12-31 | Nkr146.64 Million ≈ $15.43 Million |
Nkr15.46 Million ≈ $1.63 Million |
0.105x | +216.49% |
| 2022-12-31 | Nkr154.17 Million ≈ $16.22 Million |
Nkr-13.95 Million ≈ $-1.47 Million |
-0.090x | +41.54% |
| 2021-12-31 | Nkr174.77 Million ≈ $18.39 Million |
Nkr-27.05 Million ≈ $-2.85 Million |
-0.155x | -293.16% |
| 2020-12-31 | Nkr194.58 Million ≈ $20.48 Million |
Nkr-7.66 Million ≈ $-806.16K |
-0.039x | +61.84% |
| 2019-12-31 | Nkr208.24 Million ≈ $21.91 Million |
Nkr-21.48 Million ≈ $-2.26 Million |
-0.103x | -132.78% |
| 2018-12-31 | Nkr245.87 Million ≈ $25.87 Million |
Nkr-10.90 Million ≈ $-1.15 Million |
-0.044x | +53.27% |
| 2017-12-31 | Nkr196.48 Million ≈ $20.67 Million |
Nkr-18.63 Million ≈ $-1.96 Million |
-0.095x | -38.67% |
| 2016-12-31 | Nkr115.54 Million ≈ $12.16 Million |
Nkr-7.90 Million ≈ $-831.48K |
-0.068x | -40.53% |
| 2015-12-31 | Nkr95.06 Million ≈ $10.00 Million |
Nkr-4.63 Million ≈ $-486.79K |
-0.049x | +81.55% |
| 2014-12-31 | Nkr7.39 Million ≈ $778.15K |
Nkr-1.95 Million ≈ $-205.27K |
-0.264x | -117.56% |
| 2013-12-31 | Nkr1.62 Million ≈ $170.46K |
Nkr2.43 Million ≈ $256.10K |
1.502x | -- |
About Gentian Diagnostics AS
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and… Read more